Latest Intelligence on Biotechnology in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

A European home for orphan drugs

Published By Datamonitor
15 Feb 2001
CommentWire
CommentWire

Abbott Laboratories/Vysis: agreement for cancer tests

Published By Datamonitor
09 Apr 2001
Expert View
Expert View

Acute respiratory distress syndrome: searching for effective therapies

Acute respiratory distress syndrome has an annual incidence of up to 75 cases per 100,000 in the US. The condition remains very difficult to treat with a mortality rate between 30% and 60%. Although much research into ARDS has been carried out, the lack of a standard definition for the condition has made trial results unclear, so what hope is there of a treatment breakthrough in the near future?

Published By Datamonitor
23 Aug 2002
Expert View
Expert View

Amgen and GlaxoSmithKline dominate proceedings at ECCEO-11 with Prolia presentations

Amgen's and GlaxoSmithKline's main goal at ECCEO-11 was to educate delegates regarding Prolia's unique mechanism of action and its key differentiators, such as its mode of administration and efficacy. Long-term safety data were presented in an attempt to address Phase III trial issues; however, it is unlikely that physicians will be persuaded to use Prolia as a first-line therapy in the near term.

Published By Datamonitor
06 Apr 2011
CommentWire
CommentWire

Amgen: Aranesp closer to blockbuster status

New data shows that Johnson & Johnson's Eprex, marketed in the EU, is far more likely to cause pure red cell aplasia than two other recombinant versions. This absolute risk is low - but even so, the Eprex issue could significantly benefit Amgen's recently launched successor drug, Aranesp.

Published By Datamonitor
23 May 2002
CommentWire
CommentWire

Anadys: hepatitis C grant should boost research

The German government has awarded US-based biotech company Anadys a grant to identify proteins involved in hepatitis C transmission. Anadys' novel approach to drug development could well result in the development of more effective products, which would enhance the company's position in the anti-infectives field.

Published By Datamonitor
02 Jul 2002
CommentWire
CommentWire

Antigenics: Oncophage EU marketing application likely to fail

Antigenics is seeking EU approval for Oncophage in early-stage renal cell carcinoma. Despite there currently being no approved drugs for the post-surgical treatment of adjuvant kidney cancer in the EU or US, Oncophage's application is expected to fail. Antigenics will have to provide more robust evidence of Oncophage's efficacy if it wishes to gain approval in the lucrative US and EU markets.

Published By Datamonitor
22 Oct 2009
CommentWire
CommentWire

Antisoma/Roche: a powerful alliance

Roche will take over the development of Antisoma's oncology products, including lead drugs Pentumomab and Therex. The deal, which could be worth over $500 million, should benefit both companies. It plugs gaps in Roche's near-term R&D pipeline, while giving Antisoma the benefit of Roche's development and marketing expertise.

Published By Datamonitor
18 Nov 2002
CommentWire
CommentWire

Antisoma: changing product range, but not direction

Published By Datamonitor
30 Oct 2000
Expert View
Expert View

Are new multiple sclerosis treatments about to rock the market?

Multiple sclerosis is a chronic and unpredictable disorder, with debilitating physical and mental symptoms. However, there are few approved treatments - and most of the ones that do exist are largely confined to speeding recovery from acute attacks of the disorder or to managing symptoms. Will new pipeline MS drugs steal the market leaders' hold?

Published By Datamonitor
25 Jan 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.